Bullish & Foolish
--
--

Is P3 Health Partners going out of business?

Loading the full analysis
Reading the filings

P3 Health Partners Inc. (PIII) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

P3 Health Partners Inc. (PIII) scores 29 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 29/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $61.7M
Last close $8.50
Revenue growth (YoY) 2.8%
FCF margin (TTM) -15.8%
Dividend yield 0.0%

Leading signal: ROIC: -69.37%

Five questions, kept separate

Survival - Critical
1-2 mo of estimated runway from 2026-06-30, based on $21.3M of cash and short-term investments against $233M of annual burn. Debt pressure is the other decisive risk.
Business quality - Poor
-9.9% operating margin and -15.5% FCF margin produce a poor Business Quality assessment.
Trajectory - Mixed
Revenue weakened 2.8%; operating margin improved 2.8pp.
Valuation - Extreme expectations
-181.4% FCF yield supports an extreme expectations Valuation assessment on the derived ttm basis.
Event risk - Evidence unavailable
No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

  • ROIC: -69.37%
  • Debt / Equity: 2.08x
  • Return on Assets: -15.04%
  • Revenue CAGR (3Y): 11.61%
  • Debt Maturity Runway: 82% long-term (Long-term focused)
  • Revenue growth YoY: 8.60% (YoY)
  • Price / Sales: 0.0x (see Valuation)
  • Price / Earnings: Unprofitable (see Valuation)
  • Shares dilution YoY: 1.90% (YoY)
  • Effective Tax Rate: 4.74% (loss-making)
  • R&D intensity: 0.00%

Read from filings through 2026-08-10.

Price as of 2026-09-09.

Headline score detail

Source coverage and limitations
--
Reference Links